Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 17, 2013British Journal of Haematology

Bortezomib induces clinical remission and reduction of ADAMTS 13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMarshall MazepaUniversity of MinnesotaJRJay S. RavalUniversity of VermontSMStephan MollBank of America

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mazepa et al. (2013) studied this question.

synapsesocial.com/papers/6a9fe79400f21bf9f8ec72bahttps://doi.org/10.1111/bjh.12696
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1How I treat patients with thrombotic thrombocytopenic purpura: 20102010 · 471 citations
  2. 2A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura2011 · 433 citations
  3. 3ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura2013 · 125 citations
  4. 4Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis2005 · 1,133 citations
  5. 5von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome1998 · 1,674 citations